GlobalData analyst Shehroz Mahmood notes that Novo Nordisk's amycretin could become the "next frontier" in obesity and T2D.

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting ...

The efficacy evaluable data set comprised 21 participants. Credit: NMK-Studio/Shutterstock.com. Synthekine has reported positive initial data from a Phase Ia/Ib trial evaluating STK-012 in first-line, ...

Contineum Therapeutics’ M1 antagonist, PIPE-307, has failed to meet its primary and secondary efficacy endpoints in a Phase II trial in RRMS. Image credit: Andrzej Rostek via ShutterStock.com.

The trial aims to provide safety and efficacy data for submissions to regulatory agencies in the US and Europe. Credit: rathshiki / Shutterstock.com. Vir Biotechnology has concluded subject enrolment ...

The trial enrolled 73 subjects who had not responded satisfactorily to a minimum of one antidepressant during their current episode. Credit: daniiD / Shutterstock.com. Neurocrine Biosciences has ...

If approved in AFRS, it would become the ninth US approved indication for Dupixent. Image credit: Angelina Avei / Shutterstock.com Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ...

The WHO will support initiative implementation, foster dialogue, and mobilise resources for priority research with Member States and stakeholders. Credit: Richard Juilliart / Shutterstock.com. The ...

Roche’s oral BTK inhibitor, fenebrutinib, has demonstrated its efficacy in two different subsets of multiple sclerosis (MS) during two late-stage trials. Image credit: illustrissima via ...

Amid geopolitical instability, professionals in the clinical trials segment must look to mitigate risks early through operational flexibility. Image credit: Athanasios Psimadis / Arena International.